International Journal of Clinical Pharmacy

, Volume 36, Issue 4, pp 815–820 | Cite as

Clozapine-induced blood dyscrasias in Saudi Arab patients

  • Norah O. AbanmyEmail author
  • Afnan Al-Jaloud
  • Aisha Al-Jabr
  • Rana Al-Ruwaisan
  • Walaa Al-Saeed
  • Solafa Fatani
Research Article


Background Clozapine has shown superior efficacy over other antipsychotics. However, its use is complicated by the development of life-threatening hematologic adverse effects. Objectives This paper reports the incidence of clozapine-induced hematologic toxicity in Saudi Arab patients. Setting King Khalid University Hospital, Riyadh, Saudi Arabia. Methods Medical data of Saudi Arab hospitalized patients receiving clozapine was retrospectively reviewed during the period between August 2009 and August 2012. White blood cell (WBC) counts and differentials were recorded in a specific form to watch for any hematologic toxicity. The hematologic toxicities included in this report are: eosinophilia, thrombocytopenia, lymphocytopenia, and agranulocytosis/neutropenia/leukopenia combined. Main outcome measure Complete WBC count. Results During the study period 147 charts were reviewed. The mean age of patients was 38 ± 11.42 years and 52 % were males. During the study period 61 patients (42 %) developed 82 blood dyscrasias. Sixteen patients (10.9 %) developed agranulocytosis, neutropenia and leukopenia combined, while nineteen patients (12.9 %) developed lymphocytopenia, and seven patients (4.8 %) developed thrombocytopenia. Eosinophilia developed in 40 patients (27.2 %). During the first 18 weeks of therapy with clozapine, 21 (26 %) hematologic side effects were developed. Conclusion The data collected in this study does appear to indicate there may be an increased incidence of blood dyscrasias in Saudi Arabs which warrants further, more detailed, study. It would be of concern to psychiatric clinicians if the case of a genetic predisposition to clozapine-induced blood dyscrasias were proven in the future.


Agranulocytosis Clozapine Drug reactions Saudi Arabia 



The authors are grateful to pharmacist Reem Alharbi for her help in accessing patients’ files.


This research project was supported by a Grant from the “Research Center of the Center for Female Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud University.

Conflicts of interest

The authors have no conflicts of interest to declare.


  1. 1.
    Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990–9.PubMedGoogle Scholar
  3. 3.
    Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Hall RL, Smith AG, Edwards JG. Haematological safety of antipsychotic drugs. Expert Opin Drug Saf. 2003;2(4):395–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Oyesanmi O, Kunkel EJ, Monti DA, Field HL. Hematologic side effects of psychotropics. Psychosomatics. 1999;40(5):414–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry. 1988;49(7):271–7.PubMedGoogle Scholar
  7. 7.
    Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust. 1998;168(10):495–7.PubMedGoogle Scholar
  8. 8.
    Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.Google Scholar
  9. 9.
    Munroe J, O’Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576–80.CrossRefGoogle Scholar
  10. 10.
    BNF 62. British National Formulary. London: BMJ publishing and RPS publishing; 2011.Google Scholar
  11. 11.
    Lieberman JA, Yunis J, Eqea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47(10):945–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Amar A, Segman RH, Shtrussberg S, Sherman L, Safirman C, Lerer B, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol. 1998;1:41–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet. 1998;25(1):11–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Lahdelma L, Ahokas A, Andersson LC, Suvisaari J, Hovatta I, Huttunen MO, et al. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol. 2001;21(1):4–7.Google Scholar
  15. 15.
    Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 2007;7(5):325–32.PubMedCrossRefGoogle Scholar
  16. 16.
  17. 17.
    Landaw SA, George JN. 2013. Approach to the adult patient with thrombocytopenia. [ONLINE] Accessed 5 March 2014.
  18. 18.
    Coates T. 2013. Approach to the patient with lymphocytosis or lymphocytopenia. [ONLINE] Accessed 5 March 2014.
  19. 19.
  20. 20.
    Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. 2007;33(5):1221–4.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. BJP. 1996;169:483–8.CrossRefGoogle Scholar
  22. 22.
    Pirmohamed M, Park K. Mechanism of clozapine induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 1997;7:139–58.PubMedCrossRefGoogle Scholar
  23. 23.
    Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23:27–41.CrossRefGoogle Scholar
  24. 24.
    Kadasah S, Arfin M, Tariq M. HAL-DRB1 association with schizophrenia in Saudi Arabian patients. Int J Psychiatry Clin Pract. 2011;15:112–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Denic S, Showqi S, Klein C, Takala M, Nagelkerke N, Agarwal MM. Prevalence, phenotype and inheritance of benign neutropenia in Arabs. BMC Blood Disord. 2009;9:3.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Jumean HG, Sudah FI. Chronic benign idiopathic neutropenia in Jordanians. Acta Haematol. 1983;69:59–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Kaab SA, Fadhli SA, Burhamah M, Aljafar H, Khamis A. Lymphocyte subsets in healthy adult Kuwaiti Arabs with relative benign ethnic neutropenia. Immunol Lett. 2004;91:49–53.CrossRefGoogle Scholar
  28. 28.
    Hsieh MM, Everhart JE, Byrd-holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146:486–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Dust R, Dorevitch A, Franenkel Y. Platelet dysfunction associated with clozapine therapy. South Med J. 1993;86:1170–2.CrossRefGoogle Scholar
  30. 30.
    Assion HJ, Kolbinger HM, Rao ML, Laux G. Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. Pharmacopsychiatry. 1996;29(6):227–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Delilers GL. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica. 2000;85(3):233–7.Google Scholar
  32. 32.
    Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry. 1993;54(12):466–9.PubMedGoogle Scholar
  33. 33.
    Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. Clozapine-induced transient white blood count disorders. J Clin Psychiatry. 1994;55(10):429–32.PubMedGoogle Scholar
  34. 34.
    Coşar B, Taner ME, Eser HY, Altınöz AE, Tarhan R. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients. J Clin Psychopharmacol. 2011;31(2):169–73.PubMedCrossRefGoogle Scholar
  35. 35.
    Ben-Yehuda A, Bloom A, Lijovetzky G, Flusser D, Tur-Kaspa R. Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis. Isr J Med Sci. 1990;26(8):449–51.PubMedGoogle Scholar
  36. 36.
    Hirshberg B, Gural A, Caraco Y. Zuclopenthixol-associated neutropenia and thrombocytopenia. Ann Pharmacother. 2000;34(6):740–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Clozapine. In: DRUGDEX system [CD-ROM]. Volume 159. Truven Health Analytics; 2014 (expires March 2014).Google Scholar
  38. 38.
    Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med. 1992;119:254–6.PubMedGoogle Scholar
  39. 39.
    Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatric Serv. 1996;47:52–6.Google Scholar
  40. 40.
    Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry. J Clin Psychiatry. 1998;59(Suppl 3):3–7.PubMedGoogle Scholar
  41. 41.
    Mendelowitz AJ, Gerson SL, Alvir JJ, Lieberman JA. Clozapine-induced agranulocytosis. Risk factors, monitoring and management. CNS Drugs. 1995;4:412–21.CrossRefGoogle Scholar
  42. 42.
    Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood. 1995;86:1177–83.PubMedGoogle Scholar
  43. 43.
    Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, et al. Tumor necrosis factor constellation polymorphism and clozapine induced agranulocytosis in two different ethnic groups. Blood. 1997;89:4167–74.PubMedGoogle Scholar
  44. 44.
    Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics. 2008;9(8):1101–11.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Norah O. Abanmy
    • 1
    Email author
  • Afnan Al-Jaloud
    • 1
  • Aisha Al-Jabr
    • 1
  • Rana Al-Ruwaisan
    • 1
  • Walaa Al-Saeed
    • 1
  • Solafa Fatani
    • 2
  1. 1.Department of Clinical Pharmacy, College of PharmacyKing Saud UniversityRiyadhSaudi Arabia
  2. 2.King Khaled University HospitalRiyadhSaudi Arabia

Personalised recommendations